MENU
+Compare
GYRE
Stock ticker: NASDAQ
AS OF
Jun 30, 04:25 PM (EDT)
Price
$7.33
Change
-$0.08 (-1.08%)
Capitalization
670.2M

GYRE Gyre Therapeutics Forecast, Technical & Fundamental Analysis

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis... Show more

GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GYRE with price predictions
Jun 27, 2025

GYRE in upward trend: price may ascend as a result of having broken its lower Bollinger Band on June 02, 2025

GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where GYRE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GYRE turned negative on May 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

GYRE moved below its 50-day moving average on June 11, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on June 06, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GYRE entered a downward trend on June 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.843) is normal, around the industry mean (16.366). GYRE has a moderately high P/E Ratio (370.500) as compared to the industry average of (58.189). GYRE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (7.530) is also within normal values, averaging (252.247).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GYRE is expected to report earnings to fall 95.24% to -5 cents per share on November 13

Gyre Therapeutics GYRE Stock Earnings Reports
Q3'23
Est.
$-0.05
Q2'23
Missed
by $0.98
Q1'23
Beat
by $0.22
Q4'22
Missed
by $18.94
Q3'22
Missed
by $2.30
The last earnings report on August 03 showed earnings per share of -104 cents, missing the estimate of -7 cents. With 70.85K shares outstanding, the current market capitalization sits at 670.20M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
12770 High Bluff Drive
Phone
+1 619 949-3681
Employees
4
Web
https://www.gyretx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYLCX76.200.82
+1.09%
Rydex Leisure C
MGFLX10.300.09
+0.88%
MassMutual Global Adm
TCLCX22.110.10
+0.45%
Nuveen Large Cap Value A
ARIQX10.460.04
+0.38%
Aristotle Value Eq I
GAUAX5.12N/A
N/A
Gabelli Utilities A

GYRE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been closely correlated with SPHDF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if GYRE jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
+0.54%
SPHDF - GYRE
82%
Closely correlated
N/A
SPRC - GYRE
38%
Loosely correlated
+0.72%
BEAM - GYRE
38%
Loosely correlated
-1.98%
AURA - GYRE
37%
Loosely correlated
-0.16%
OCGN - GYRE
37%
Loosely correlated
-4.46%
More